These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

563 related items for PubMed ID: 16356805

  • 1. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
    Rouleau J.
    Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
    [Abstract] [Full Text] [Related]

  • 2. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR, Giugliano RP, Mohanavelu S, Murphy SA, McCabe CH, Cannon CP, Braunwald E.
    J Am Coll Cardiol; 2008 Sep 09; 52(11):914-20. PubMed ID: 18772061
    [Abstract] [Full Text] [Related]

  • 3. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
    Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E.
    J Am Coll Cardiol; 2009 Dec 15; 54(25):2358-62. PubMed ID: 20082923
    [Abstract] [Full Text] [Related]

  • 4. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
    Murphy SA, Cannon CP, Wiviott SD, de Lemos JA, Blazing MA, McCabe CH, Califf RM, Braunwald E.
    Am J Cardiol; 2007 Oct 01; 100(7):1047-51. PubMed ID: 17884359
    [Abstract] [Full Text] [Related]

  • 5. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
    Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators.
    N Engl J Med; 2004 Apr 08; 350(15):1495-504. PubMed ID: 15007110
    [Abstract] [Full Text] [Related]

  • 6. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
    Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E, PROVE IT-TIMI 22 Investigators.
    J Am Coll Cardiol; 2005 Oct 18; 46(8):1405-10. PubMed ID: 16226162
    [Abstract] [Full Text] [Related]

  • 7. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
    Gibson CM, Pride YB, Hochberg CP, Sloan S, Sabatine MS, Cannon CP, TIMI Study Group.
    J Am Coll Cardiol; 2009 Dec 08; 54(24):2290-5. PubMed ID: 19958964
    [Abstract] [Full Text] [Related]

  • 8. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.
    Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E, PROVE IT-TIMI 22 Investigators.
    J Am Coll Cardiol; 2005 Oct 18; 46(8):1411-6. PubMed ID: 16226163
    [Abstract] [Full Text] [Related]

  • 9. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?
    Ray KK, Cannon CP.
    Am J Cardiol; 2005 Sep 05; 96(5A):54F-60F. PubMed ID: 16126024
    [Abstract] [Full Text] [Related]

  • 10. Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada.
    Austin PC, Mamdani MM.
    Circulation; 2005 Aug 30; 112(9):1296-300. PubMed ID: 16116054
    [Abstract] [Full Text] [Related]

  • 11. Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study).
    Tung P, Wiviott SD, Cannon CP, Murphy SA, McCabe CH, Gibson CM.
    Am J Cardiol; 2009 Apr 15; 103(8):1056-60. PubMed ID: 19361589
    [Abstract] [Full Text] [Related]

  • 12. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
    Brilakis ES, de Lemos JA, Cannon CP, Wiviott SD, Murphy SA, Morrow DA, Sabatine MS, Banerjee S, Blazing MA, Califf RM, Braunwald E.
    Am J Cardiol; 2008 Sep 01; 102(5):552-8. PubMed ID: 18721511
    [Abstract] [Full Text] [Related]

  • 13. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
    Ray KK, Cannon CP, Cairns R, Morrow DA, Rifai N, Kirtane AJ, McCabe CH, Skene AM, Gibson CM, Ridker PM, Braunwald E, PROVE IT-TIMI 22 Investigators.
    J Am Coll Cardiol; 2005 Oct 18; 46(8):1417-24. PubMed ID: 16226164
    [Abstract] [Full Text] [Related]

  • 14. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study).
    Khera AV, Wolfe ML, Cannon CP, Qin J, Rader DJ.
    Am J Cardiol; 2010 Aug 15; 106(4):451-6. PubMed ID: 20691300
    [Abstract] [Full Text] [Related]

  • 15. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.
    Gresser U, Gathof BS.
    Eur J Med Res; 2004 Jan 26; 9(1):1-17. PubMed ID: 14766335
    [Abstract] [Full Text] [Related]

  • 16. Are Canadian guidelines for cholesterol lowering in high-risk patients optimal?
    Fitchett DH, Leiter LA, Tardif JC, Goodman S, Langer A.
    Can J Cardiol; 2005 Jan 26; 21(1):85-90. PubMed ID: 15685308
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
    McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW, STELLAR Study Group.
    Curr Med Res Opin; 2003 Jan 26; 19(8):689-98. PubMed ID: 14687438
    [Abstract] [Full Text] [Related]

  • 18. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets (TNT) Investigators.
    N Engl J Med; 2005 Apr 07; 352(14):1425-35. PubMed ID: 15755765
    [Abstract] [Full Text] [Related]

  • 19. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
    Nissen SE.
    Am J Cardiol; 2005 Sep 05; 96(5A):61F-68F. PubMed ID: 16126025
    [Abstract] [Full Text] [Related]

  • 20. Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study.
    Zhao SP, Peng DQ, Yu BL, Huo Y, CHILLAS investigators.
    Am Heart J; 2009 Oct 05; 158(4):509-512.e1. PubMed ID: 19781407
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.